Biotech Acquisition Overview
Latest ROE for Biotech Acquisition: -1.01% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-100.90%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Biotech Acquisition (BIOT) currently reports a ROE of -1.01%. That is below the sector sector average of -4.03%. Use the charts on this page to explore Biotech Acquisition's ROE history and peer comparisons.
Biotech Acquisition's ROE of -1.01% is lower than the its sector sector average of -4.03%. That is roughly 2406.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Biotech Acquisition's current -1.01% should be judged against industry norms (sector average: -4.03%) and against BIOT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -1.01%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -4.03%. From there, open related valuation or income-statement pages for Biotech Acquisition, and consider following BIOT for alerts when major investors trade the stock.
